Zoetis Inc. Payments for Hedge, Financing Activities
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Zoetis Inc. payments for hedge, financing activities for fiscal 2025 was $187.00M.
- Zoetis Inc. payments for hedge, financing activities for fiscal 2024 was $0.00.
- Zoetis Inc. payments for hedge, financing activities for fiscal 2023 was $0.00.
| Period end | Payments for Hedge, Financing Activities 3 month | Payments for Hedge, Financing Activities 12 month |
|---|---|---|
| 2025-12-31 | $187.00M 10-K · filed 2026-02-12 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-12 | |
| 2023-12-31 | $0.00 10-K · filed 2026-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |